Shared on01 May 25Fair value Increased 1.17%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
24 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$12.67
64.0% undervalued intrinsic discount15 Aug
US$4.56
1Y
-14.8%7D
8.8%